Correction to "Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP<sub>2</sub> Receptor Antagonist for Treatment of Asthma".

导出 OA

翻译打印收藏纠错

作者： David A,Sandham ^[1] ; Lucy,Barker ^[1] ; Lyndon,Brown ^[1] ; Zarin,Brown ^[1] ; David,Budd ^[1] ; Steven J,Charlton ^[1] ; Devnandan,Chatterjee ^[1] ; Brian,Cox ^[1] ; Gerald,Dubois ^[1] ; Nicholas,Duggan ^[1] ; Edward,Hall ^[1] ; Julia,Hatto ^[1] ; Catherine,Leblanc ^[1] ; Janet,Maas ^[1] ; Jodie,Manini ^[1] ; Rachael,Profit ^[1] ; Darren,Riddy ^[1] ; Catherine,Ritchie ^[1] ; Bindi,Sohal ^[1] ; Duncan,Shaw ^[1] ; Rowan,Stringer ^[1] ; David A,Sykes ^[1] ; Matthew,Thomas ^[1] ; Katharine L,Turner ^[1] ; Simon J,Watson ^[1] ; Ryan,West ^[1] ; Elisabeth,Willard ^[1] ; Gareth,Williams ^[1] ; Jennifer,Willis ^[1]

作者单位： Novartis Institutes for Biomedical Research, Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom. ^[1]

DOI 10.1021/acsmedchemlett.7b00353

PMID 28947949

发布时间 2020-10-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览9

ACS medicinal chemistry letters

2017年8卷9期

987页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Correction to "Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP<sub>2</sub> Receptor Antagonist for Treatment of Asthma".

ACS medicinal chemistry letters

相似文献

ACS medicinal chemistry letters

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Correction to "Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP<sub>2</sub> Receptor Antagonist for Treatment of Asthma".

ACS medicinal chemistry letters

相似文献

ACS medicinal chemistry letters

相关期刊

检索历史清除